Cover Image

Involvement of poly(ADP-ribose) polymerase-1 in development of spinal cord injury in Chinese individuals: a Chinese clinical study

Qing-Tao Meng,* Guang Yang,* Ren-Bo Li, Jing-Xin Nie, Wei Zhou, Hong-De Yu, Bo Chen, Li Jiang, Jing-Bo Shang Department of Spine Surgery, The Third People’s Hospital of Dalian, Dalian, People’s Republic of China *These authors contributed equally to this work Objective: We aimed...

Full description

Saved in:

Bibliographic Details
Main Authors:	Meng Q (Author), Yang G (Author), Li R (Author), Nie J (Author), Zhou W (Author), Yu H (Author), Chen B (Author), Jiang L (Author), Shang J (Author)
Format:	Book
Published:	Dove Medical Press, 2017-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
by: Chia-Hao Liu, et al.
Published: (2017)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
by: Stephen A. Jannetti, et al.
Published: (2020)

The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis
by: Samuel García, et al.
Published: (2015)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
by: Ruihong Dong, et al.
Published: (2023)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
by: Stergios Boussios, et al.
Published: (2020)

Poly (ADP-Ribose) Polymerase Mediates Diabetes-Induced Retinal Neuropathy
by: Ghulam Mohammad, et al.
Published: (2013)

Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
by: Sarkar Oli, et al.
Published: (2009)

Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach
by: Zaffini R, et al.
Published: (2018)

Targeted therapy with Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of solid tumours
by: Faustyna Piędel, et al.
Published: (2020)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
by: Qin Xu, et al.
Published: (2021)

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
by: Zhimin Zhang, et al.
Published: (2020)

Role of poly (ADP-ribose) polymerase-1 and NF-kappaB as potential risk factor in the development of non-small cell lung cancer in Chinese individuals
by: Anguo Chen, et al.
Published: (2018)

Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment
by: Zhao D, et al.
Published: (2022)

Regulation of HIV-1 replication by Poly (ADP-ribose) polymerase-1 in CD4 T cells.
by: M. Llano, et al.
Published: (2017)

Decreasing Poly(ADP-ribose) Polymerase activity restores ΔF508 CFTR trafficking
by: Suzana Maria Anjos, et al.
Published: (2012)

Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review
by: Vivien Kin Yi Chan, et al.
Published: (2022)

Roles of poly(ADP-ribose) polymerase 1 and mitophagy in progeroid syndromes as well as physiological ageing
by: Naoko Suga, et al.
Published: (2023)

24 Correlation of clinical outcomes and poly ADP ribose polymerase activity in high grade serous ovarian cancer
by: Elaine T. Fleming, et al.
Published: (2023)

Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification
by: George Nassief, BA, et al.
Published: (2024)

Poly ADP-ribose polymerase (PARP) inhibitors - new therapeutic strategies in Acute Myeloid Leukemia: a literature review
by: Emilia Nowicka, et al.
Published: (2022)

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
by: Jingcao Zheng, et al.
Published: (2023)

Poly (ADP-Ribose) Polymerase 1 Mediated Arginase II Activation Is Responsible for Oxidized LDL-Induced Endothelial Dysfunction
by: Qi Wang, et al.
Published: (2018)

Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Diabetic Retinopathy: An Attractive but Elusive Choice for Drug Development
by: Etelka Pöstyéni, et al.
Published: (2024)

Inhibition of poly(ADP-ribose)polymerase contributes to the reduction of oxidative stress in murine liver under the conditions of experimental endotoxemia
by: N. H. Hrushka, et al.
Published: (2019)

Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials
by: Liu Y, et al.
Published: (2018)

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP‐ribose) Polymerase‐1 Inhibitor, JPI-289, in Healthy Volunteers
by: Han S, et al.
Published: (2020)

Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease
by: Emanuela Paldino, et al.
Published: (2017)

1-Oxo-3,4-dihydroisoquinoline-4-carboxamides as novel druglike inhibitors of poly(ADP-ribose) polymerase (PARP) with favourable ADME characteristics
by: Alexander Safrygin, et al.
Published: (2021)

Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?
by: Yiu-Tai Li, et al.
Published: (2024)

Garmultin-A Incites Apoptosis in CB3 Cells Through miR-17-5p by Attenuating Poly (ADP-Ribose) Polymerase-1
by: Jianfei Qiu, et al.
Published: (2022)

Small interfering RNA mediated Poly (ADP-ribose) Polymerase-1 inhibition upregulates the heat shock response in a murine fibroblast cell line
by: Zingarelli Basilia, et al.
Published: (2011)

Expression of poly(Adenosine Diphosphate-Ribose) polymerase protein in breast cancer
by: Akanksha, et al.
Published: (2022)

Three-component Castagnoli-Cushman reaction with ammonium acetate delivers 2-unsubstituted isoquinol-1-ones as potent inhibitors of poly(ADP-ribose) polymerase (PARP)
by: Alexander Safrygin, et al.
Published: (2021)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data
by: Quanfeng Zhao, et al.
Published: (2022)

Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data
by: Quanfeng Zhao, et al.
Published: (2022)

Piceid Octanoate Protects Retinal Cells against Oxidative Damage by Regulating the Sirtuin 1/Poly-ADP-Ribose Polymerase 1 Axis In Vitro and in rd10 Mice
by: Seyed Mohamadmehdi Moshtaghion, et al.
Published: (2024)

A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy
by: Nan Zhang, et al.
Published: (2024)

Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis
by: Min Tang, et al.
Published: (2024)

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials
by: Lin Fan, et al.
Published: (2022)

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
by: Xiaosa Chang, et al.
Published: (2021)